ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ADARx Pharmaceuticals (ADRX) reported third-quarter 2026 results and completed financings generating approximately $602.5 million in aggregate gross proceeds. The IPO comprised 30,187,500 shares at $17.00 each; the concurrent AbbVie private placement comprised 5,255,542 shares. Cash, cash equivalents and short-term investments totaled $901.0 million at September 30, excluding approximately $62.3 million in net option-exercise proceeds received October 1. ADARx expects these funds to support operations into 2030.
Quarterly collaboration revenue rose to $2.217 million from $1.555 million a year earlier, while net loss widened to $28.117 million from $17.883 million. Three agazisiran Phase 2 trials advanced, and onvuzosiran received FDA Fast Track designation for hereditary angioedema prevention. ADARx expects agazisiran data during 2027 and onvuzosiran Phase 3 topline data by year-end 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointIPO and concurrent AbbVie private placement generated approximately $602.5 million in aggregate gross proceeds. 42% of market cap
- Moderate pointThird-quarter collaboration revenue increased to $2.217 million from $1.555 million in 2025.
- Moderate pointAgazisiran advanced three Phase 2 trials covering renal diseases, paroxysmal nocturnal hemoglobinuria and geographic atrophy.
- Minor pointCash, equivalents and short-term investments totaled $901.0 million at September 30, 2026, excluding October option proceeds.
- Minor pointUnderwriters’ option exercise added approximately $62.3 million net proceeds on October 1, 2026.
11 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.ADARx expects existing funds and October option proceeds to fund operating expenses and capital requirements into 2030.
- Minor pointNine-month collaboration revenue increased to $5.103 million from $1.763 million in 2025.
- Minor pointOnvuzosiran received FDA Fast Track designation in August 2026 for prevention of hereditary angioedema attacks.
- Minor point. Forward-looking: it has not happened yet and may not happen.Agazisiran IgAN data are anticipated mid-2027 for nine-month urine protein reduction and 2H 2027 for one-year kidney-function stabilization.
- Minor point. Forward-looking: it has not happened yet and may not happen.Agazisiran Phase 2 data in C3G and paroxysmal nocturnal hemoglobinuria are anticipated in 2H 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.Onvuzosiran Phase 3 STOP-HAE topline data are anticipated by year-end 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.ADX-626 Phase 2a/b initiation for secondary stroke prevention is anticipated in 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.ADX-626 planning includes exploratory studies for stroke prevention in patients with atrial fibrillation.
- Minor point. Forward-looking: it has not happened yet and may not happen.ADX-077 Phase 1 initiation in obesity is anticipated in 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.ADX-199 Phase 1 initiation is anticipated by year-end 2027 or early 2028.
- Minor pointThird-quarter loss per share narrowed to $1.74 from $1.85 in 2025.
Negative
- Major pointIPO issuance of 30,187,500 shares at $17.00 dilutes existing holders.
- Moderate pointThird-quarter net loss widened to $28.117 million from $17.883 million in 2025.
- Moderate pointThird-quarter research and development expenses rose to $26.713 million from $19.416 million in 2025.
- Minor pointConcurrent AbbVie private placement issued 5,255,542 shares, adding dilution.
- Minor pointNine-month net loss widened to $76.543 million from $51.527 million in 2025.
5 minor points
- Minor pointNine-month research and development expenses rose to $75.032 million from $49.381 million in 2025.
- Minor pointThird-quarter general and administrative expenses rose to $7.681 million from $5.146 million in 2025.
- Minor pointNine-month general and administrative expenses rose to $19.195 million from $14.399 million in 2025.
- Minor pointThird-quarter interest income fell to $3.479 million from $4.622 million in 2025.
- Minor pointNine-month loss per share widened to $6.46 from $5.35 in 2025.
News Explained
ADARx completed its IPO and concurrent AbbVie placement, issuing 30,187,500 and 5,255,542 new shares, respectively; these issuances increase the share count and reduce existing holders’ percentage ownership, absent offsetting changes.
Key Figures
- Aggregate gross proceeds
- Approximately $602.5 million
- IPO and concurrent private placement
- Cash and short-term investments
- $901.0 million
- As of September 30, 2026
- Cash runway
- Into 2030
- Expected funding for projected operating expenses and capital expenditure requirements
- Collaboration revenue
- $2.2 million vs. $1.6 million
- Third quarter 2026 vs. third quarter 2025
- Net loss
- $28.1 million vs. $17.9 million
- Third quarter 2026 vs. third quarter 2025
- Ongoing Phase 2 trials
- Three trials
- Agazisiran in complement-mediated diseases
- Topline data timing
- By year-end 2027
- Phase 3 STOP-HAE trial of onvuzosiran
Historical Context
-
IPO and AbbVie private placement raised approximately $602.5 million gross; IPO shares were priced at $17.00.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
sirna medical
fast track designation regulatory
upcr medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Completed initial public offering (IPO) and concurrent private placement generating aggregate gross proceeds of approximately
– Advanced three Phase 2 clinical trials for agazisiran for the treatment of complement-mediated diseases –
– Received Fast Track designation for onvuzosiran for HAE –
SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (“ADARx” or the “Company”) (Nasdaq: ADRX), a late-clinical stage biotechnology company developing next-generation siRNA therapeutics, today reported financial results for the third quarter ended September 30, 2026, and provided a summary of recent business highlights.
“We have made significant progress across our pipeline of next-generation siRNA therapeutics, bolstered by the successful completion of our IPO and concurrent private placement. These financings provide the resources to advance three clinical-stage programs in parallel, bring two advanced preclinical candidates into the clinic, and support additional IND filings as we expand our pipeline,” said Zhen Li, Ph.D., President and Chief Executive Officer of ADARx. “As the siRNA field evolves, we see tremendous opportunity to expand the range of diseases these therapeutics can address. We believe that our progress with differentiated liver-targeted programs and targeted delivery to extrahepatic tissues positions us to advance our mission of delivering life-changing treatments to patients with unmet medical needs.”
Third Quarter 2026 and Recent Business Highlights
- Agazisiran – Advancing three Phase 2 clinical trials for the treatment of complement-mediated diseases: ADARx continued to advance three Phase 2 clinical trials ongoing in: (1) renal diseases, including IgA nephropathy (IgAN), complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); (2) paroxysmal nocturnal hemoglobinuria (PNH); and (3) geographic atrophy (GA) secondary to age-related macular degeneration (AMD), to support its potential as a pipeline-in-a-product opportunity. ADARx intends to explore additional dosing regimens in its Phase 2 IgAN and PNH clinical trials.
- Onvuzosiran – Received Fast Track designation for HAE: In August 2026, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to onvuzosiran for prophylaxis to prevent attacks of hereditary angioedema (HAE). Onvuzosiran is currently being evaluated in the Phase 3 STOP-HAE clinical trial (NCT06960213).
- ADX-626 – Advanced clinical development and Phase 2 planning in secondary stroke prevention (SSP) and stroke prevention in atrial fibrillation (AFib): Phase 2 planning for ADARx’s Factor XI (FXI) program is underway for development in SSP and for exploratory studies in stroke prevention in patients with AFib. Determination has been made to not evaluate higher doses after the third dose cohort (400 mg) in the ongoing Phase 1 trial, and the Company intends to evaluate higher doses in its planned Phase 2 clinical trial.
- Closed IPO and concurrent private placement for aggregate gross proceeds of approximately
$602.5 million : ADARx closed its IPO of 30,187,500 shares of its common stock, including 3,937,500 shares issued and sold on October 1, 2026 upon the underwriters’ exercise in full of their option to purchase additional shares, at a price of$17.00 per share. All of the shares of common stock were offered by ADARx and gross proceeds from the IPO, before deducting underwriting discounts and commissions and other offering expenses, were$513.2 million . Together with gross proceeds of$89.3 million from the 5,255,542 shares issued and sold in the concurrent private placement with AbbVie, aggregate gross proceeds from the IPO and concurrent private placement totaled approximately$602.5 million . ADARx’s common stock began trading on the Nasdaq Global Select Market under the ticker symbol “ADRX” on September 25, 2026. - Expanded leadership team with board and executive appointments: Executive leader and current K2 Therapeutics CEO, Ying Huang, Ph.D., was appointed to the Board of Directors and veteran human resources leader Robert Ackles was appointed as Chief People Officer to help guide the Company’s strategic growth.
Anticipated Key Milestones:
- Agazisiran (CFB) Phase 2 data:
- IgAN - mid-2027 (9-month UPCR reduction data), 2H 2027 (1-year eGFR stabilization data)
- C3G - 2H 2027
- PNH - 2H 2027
- Onvuzosiran (PKK): Phase 3 STOP-HAE topline data by year-end 2027
- ADX-626 (FXI): Phase 2a/b initiation in SSP in 2027
- ADX-077 (OBE1): Phase 1 initiation in obesity in 2027
- ADX-199 (APP): Phase 1 initiation by year-end 2027 or early 2028
Third Quarter 2026 Financial Results
As of September 30, 2026, ADARx had cash, cash equivalents and short-term investments of
Collaboration revenue was
Research and development (R&D) expenses were
General and administrative (G&A) expenses were
Net loss was
Upcoming Events
ADARx expects to participate in the following upcoming investor conference:
- UBS Global Biopharma Conference - London, Monday, November 16, 2026 at 2:00 pm GMT
About ADARx Pharmaceuticals
ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation RNA therapeutics designed to treat a broad spectrum of diseases. The Company is focused on advancing and expanding its pipeline of highly potent, selective and durable small interfering RNA (“siRNA”) therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. ADARx’s three hepatic-targeted programs are agazisiran, onvuzosiran and ADX-626, and its two extrahepatic-targeted programs are ADX-077 and ADX-199. Beyond its named programs, ADARx plans to continue to leverage its proprietary technologies to strategically expand its pipeline of next-generation siRNA therapeutics. ADARx’s goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding: ADARx’s cash runway; the anticipated timing of data from ADARx’s clinical trials; the anticipated initiation and timing of ADARx’s preclinical studies and clinical trials; the potential of agazisiran as a pipeline-in-a-product opportunity; the potential safety, efficacy, durability and other benefits of ADARx’s therapeutic candidates and technologies, including its extrahepatic delivery technology; ADARx's ability to advance its clinical programs in parallel, advance its preclinical candidates into clinical development and submit additional INDs; the anticipated use of the proceeds from the IPO and concurrent private placement; the potential of siRNA therapeutics to address a broader range of diseases; and ADARx’s strategy, plans and objectives. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “target,” “will,” “would” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on ADARx’s current expectations and assumptions and are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements, including risks related to the timing, progress and results of ADARx’s preclinical studies and clinical trials, ADARx’s ability to obtain regulatory clearances and approvals for its therapeutic candidates, ADARx’s reliance on third parties and ADARx’s capital needs. For a further description of these and other risks and uncertainties, see the section titled “Risk Factors” in ADARx’s final prospectus filed with the Securities and Exchange Commission (SEC) pursuant to Rule 424(b), ADARx’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the SEC and ADARx’s other filings with the SEC. Forward-looking statements speak only as of the date of this press release, and you should not place undue reliance on them. Except as required by applicable law, ADARx undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
| ADARx PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEET (IN THOUSANDS) (UNAUDITED) | ||||||||
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 570,610 | $ | 66,517 | ||||
| Short-term investments | 330,397 | 413,479 | ||||||
| Prepaid expenses and other current assets | 17,507 | 13,379 | ||||||
| Total current assets | 918,514 | 493,375 | ||||||
| Property and equipment, net | 4,397 | 4,734 | ||||||
| Operating lease right-of-use assets | 6,053 | 7,336 | ||||||
| Other non-current assets | 100 | 2,210 | ||||||
| Total assets | $ | 929,064 | $ | 507,655 | ||||
| Liabilities, convertible preferred stock, and stockholders’ equity (deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 9,346 | $ | 5,844 | ||||
| Accrued expenses and other current liabilities | 11,594 | 6,371 | ||||||
| Deferred revenue, current portion | 20,924 | 16,557 | ||||||
| Lease liabilities, current portion | 1,710 | 1,713 | ||||||
| Total current liabilities | 43,574 | 30,485 | ||||||
| Lease liabilities, less current portion | 4,749 | 6,028 | ||||||
| Deferred revenue, less current portion | 305,524 | 314,994 | ||||||
| Other long-term liabilities | 815 | 781 | ||||||
| Total liabilities | 354,662 | 352,288 | ||||||
| Commitments and contingencies | ||||||||
| Convertible preferred stock: | ||||||||
| Series A convertible preferred stock, | — | 37,553 | ||||||
| Series B convertible preferred stock, | — | 74,787 | ||||||
| Series B-1 convertible preferred stock, | — | 45,710 | ||||||
| Series C convertible preferred stock, | — | 199,572 | ||||||
| Stockholders’ equity (deficit): | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 11 | — | ||||||
| Additional paid-in capital | 873,785 | 16,489 | ||||||
| Accumulated other comprehensive (loss) income | (2,152 | ) | 1,955 | |||||
| Accumulated deficit | (297,242 | ) | (220,699 | ) | ||||
| Total stockholders’ equity (deficit) | 574,402 | (202,255 | ) | |||||
| Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) | $ | 929,064 | $ | 507,655 | ||||
| ADARx PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (IN THOUSANDS) (UNAUDITED) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue: | ||||||||||||||||
| Collaboration revenue | $ | 2,217 | $ | 1,555 | $ | 5,103 | $ | 1,763 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 26,713 | 19,416 | 75,032 | 49,381 | ||||||||||||
| General and administrative | 7,681 | 5,146 | 19,195 | 14,399 | ||||||||||||
| Total operating expenses | 34,394 | 24,562 | 94,227 | 63,780 | ||||||||||||
| Loss from operations | (32,177 | ) | (23,007 | ) | (89,124 | ) | (62,017 | ) | ||||||||
| Other income, net: | ||||||||||||||||
| Interest income | 3,479 | 4,622 | 11,234 | 9,363 | ||||||||||||
| Other income | 581 | 502 | 1,347 | 1,127 | ||||||||||||
| Total other income, net | 4,060 | 5,124 | 12,581 | 10,490 | ||||||||||||
| Net loss | $ | (28,117 | ) | $ | (17,883 | ) | $ | (76,543 | ) | $ | (51,527 | ) | ||||
| Other comprehensive income (loss): | ||||||||||||||||
| Foreign currency translation adjustment | 3 | (6 | ) | 32 | (28 | ) | ||||||||||
| Unrealized (losses) gains on available-for-sale securities | (1,372 | ) | 435 | (4,139 | ) | 1,236 | ||||||||||
| Total comprehensive loss | $ | (29,486 | ) | $ | (17,454 | ) | $ | (80,650 | ) | $ | (50,319 | ) | ||||
| Net loss per share, basic and diluted | $ | (1.74 | ) | $ | (1.85 | ) | $ | (6.46 | ) | $ | (5.35 | ) | ||||
| Weighted-average shares outstanding, basic and diluted | 16,127,078 | 9,654,689 | 11,840,561 | 9,632,648 | ||||||||||||

Contacts Investors: ir@adarx.com Media: teri@redhousecomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did ADARx raise in its IPO and concurrent private placement?
ADARx raised approximately $602.5 million in aggregate gross proceeds. The IPO generated $513.2 million before underwriting discounts, commissions and other offering expenses, while the concurrent private placement with AbbVie generated $89.3 million.
How long does ADARx expect its cash to fund operations?
ADARx expects its existing cash, cash equivalents and short-term investments, together with the October 1 option-exercise proceeds, to fund projected operating expenses and capital expenditure requirements into 2030. The September 30 balance was $901.0 million, excluding approximately $62.3 million in net proceeds received October 1.
What dosing changes is ADARx planning for agazisiran and ADX-626 trials?
ADARx intends to explore additional dosing regimens in the agazisiran Phase 2 IgAN and paroxysmal nocturnal hemoglobinuria trials and higher ADX-626 doses in its planned Phase 2 trial. Higher ADX-626 doses will not be evaluated after the third dose cohort, 400 mg, in the ongoing Phase 1 trial.